Minomic International Limited was established in 2007, as a company that commercialises late stage biotechnology development projects.
The first two diagnostic products for the detection of Prostate Cancer and the detection of Type 2 Diabetes will be Minomic International's flagship commercialisation projects.
Both diagnostic products are urine based tests and will offer significant advantages over the dominant, more invasive screening methods currently used for detecting each disease.
With the ability to identify and test reliably for biomarkers of diseases such as cancer and diabetes, Minomic International is in a niche and growing market with few rivals. The technology has major opportunities for rapid product range extension in diseases where traditional tests are limited or inadequate.
Proteomics is revolutionising protein molecular diagnostics through the discovery of protein biomarkers and panels of biomarkers that may be developed into highly predictive diagnostic tests. These tests will provide improved patient care as well as providing pharmacoproteomic services that lead to improved drug toxicology, efficacy and theranostic assays.
Minomic International has an impressive board of directors and management team, ensuring that the company is well equipped for global expansion and future development projects.
For more information on Minomic International, please contact info@minomic.com |
